Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation

Characteristics, predictive factors, and prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation

“…Assessing whether PL effusion is symptomatic or not could be arbitrary, especially in a retrospective study. Therefore, we adopted CT-based judgment on the existence of effusions, in line with several other studies 5,6,8,25 , showing the incidence of PT and PC effusions 27% 6 and 20-26% 5,8 in adult patients.…”

“…Few studies have examined cavity effusions in adult patients undergoing allo-HSCT. While the causal link between effusions and prognosis is still obscure, previous studies have suggested that cavity effusions could be surrogates for poor survival [4][5][6][7][8] . These studies examined pleural (PL), peritoneal (PT), or pericardial (PC) effusions independently, and few studies have addressed when and where cavity effusions in different locations occur and how much those are related to prognosis.…”

Successful Treatment of Massive Intractable Pericardial Effusion with Tocilizumab in a Child Undergone Allogeneic Hematopoietic Stem Cell Transplantation

“…The incidence of PE in pediatric HSCT recipients is higher than in adult patients [6,7] ,but the reported incidence in pediatric patients varies widely across centers. Increased age, high-risk patients, ablative conditioning regimens, late neutrophil engraftment, relapse, GVHD, GVHD prophylaxis, donor type, TMA, and CMV viremias have been suggested to be potential risk factor [1,2,8,9] . Previously published report from our center [4] , 25 of 446(5.6%) children with thalassemia major developing a PE after HSCT, 11 patients with large PE, 11 patients with moderate PE, and 3 patients with mild PE, most of them were secondary to pulmonary infection.…”

“…PE is a life-threatening complication in HSCT patients with a risk of cardiac tamponade. The incidence of PE varies between 0.2% and 37.8% in HSCT recipients [1][2][3][4][5] . Currently there is no standard guidelines for the treatment of PE after HSCT and the choice of treatment varies between individuals.…”